FirsthandHealth
medRxiv PreprintsInternational6 October 2026

A detectability floor for treatment-response labels in rheumatology transcriptomics

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Objectives. Before-and-after transcriptomics in rheumatic disease often yields no reproducible treatment signal, though disease-state stratification is robust. We asked whether exposure and response-prediction labels fall below the detection floor of the designs defining them, while matched disease-state labels do not. Methods. Eight public datasets were analysed (paired juvenile dermatomyositis n = 10; RA before/after methotrexate, n = 28 pairs; lupus nephritis n = 10; controlled exposures; a single-cell dose series). Response labels in current use (one benchmark trajectory, five published si
— medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.